U.S. markets close in 5 hours 11 minutes
  • S&P 500

    4,414.50
    +19.24 (+0.44%)
     
  • Dow 30

    35,089.17
    +153.70 (+0.44%)
     
  • Nasdaq

    14,743.97
    +71.29 (+0.49%)
     
  • Russell 2000

    2,243.34
    +17.09 (+0.77%)
     
  • Crude Oil

    72.54
    -1.41 (-1.91%)
     
  • Gold

    1,818.30
    +1.10 (+0.06%)
     
  • Silver

    25.53
    -0.02 (-0.07%)
     
  • EUR/USD

    1.1882
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.1890
    -0.0500 (-4.04%)
     
  • GBP/USD

    1.3910
    +0.0004 (+0.03%)
     
  • USD/JPY

    109.2750
    -0.3400 (-0.31%)
     
  • BTC-USD

    39,576.30
    -1,749.41 (-4.23%)
     
  • CMC Crypto 200

    966.43
    +5.53 (+0.58%)
     
  • FTSE 100

    7,091.53
    +59.23 (+0.84%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Biogen profit tumbles 71% on rising competition to multiple sclerosis drug

July 22 (Reuters) - Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

The company, which is facing some hesitancy from hospitals and insurers over its recently approved Alzheimer's drug Aduhelm, earned $448.5 million, or $2.99 per share, in the second quarter ended June 30, from $1.54 billion, or $9.59 per share, a year earlier. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)